- Clone:
- REA1344 | B1/35
- Type of antibody:
- Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- FC, MICS, IF, IHC Glossary
- Select a conjugate:
- Select a size:
Related products for CD248 (Endosialin) Antibody, anti-human, REAfinity™
Clone REA1344 recognizes the human CD248 antigen, also known as Endosalin, Tumor endothelial marker 1 (TEM1) or CD164 sialomucin-like 1 (CD164L1). CD248 is a single-pass type I transmembrane glycoptrotein belonging to the Group XIV, a novel family of C-type lectin transmembrane receptors. CD248 is expressed on tumor endothelial cells, in metastatic lesions of the liver pericytes and on stromal fibroblasts. CD248 is suggested to be involved in tumor angiogenesis,development and growth and in lymphoid tissue organization.
REA1344 displays negligible binding to Fc receptors.
Tumor endothelial marker 1, CD164L1, CD164 sialomucin-like 1, TEM1
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Simonavicius, N. et al. (2008) Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Mod Pathol 21 (3): 308-315
- Rettig, W. J. (1992) Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc. Natl. Acad. Sci. U.S.A. 89 (22): 10832-10836
- Khan, K. A. et al. (2019) C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation. FEBS J. 286 (17): 3299-3332
- MacFadyen, J. R. et al. (2005) Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett. 579 (12): 2569-2575
- Viski, C. et al. (2016) Endosialin-Expressing Pericytes Promote Metastatic Dissemination. Cancer Res. 76 (18): 5313-5325